EVOLUTION AT MERCK - INVENTING FOR LIFE
UNIQUE PNEUMOCOCCAL PORTFOLIO TARGETING
PROTECTION IN ADULTS AND CHILDREN
MERCK
INVENTING FOR LIFE
PNEUMOVAX 23
Foundation of adult
prevention
Unique combination of
serotype coverage and
cost effectiveness
V114
Advancing protection
across pediatric and
adult populations
Expanded serotype
coverage to potentially
address the highest
burden of pneumococcal
disease
Awarded Breakthrough Therapy Designation
in Pediatric and Adult Populations
V116
Targeted approach
to adult prevention
Focus on potential to
broaden protection in
adult population
OTHER PCVs
Aiming for broadest
protection for pediatric
population
Potential to establish
long-term leadership in
pediatric market
FOUNDATION
NEXT-GENERATION PNEUMOCOCCAL PIPELINE
Mike Nally I
64View entire presentation